Exyte and Univercells Technologies are announcing a global partnership for optimized construction of modular standardized and flexible GMP manufacturing facilities for vaccines.
Read article "New partnership with Exyte for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic"Press Releases
The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialization and commercialization of Univercells’ manufacturing technologies
Read article "€50M investment from KKR platform to accelerate the commercialization of technologies portfolio"
Univercells and consortium partner Batavia Biosciences have been awarded a $4 million grant extension by the Bill & Melinda Gates Foundation to scale up their low-cost polio vaccine manufacturing technology.
Read article "Introducing the NevoLine™ sIPV platform"
Univercells Receives $12 Million Grant to Develop Breakthrough Vaccine Manufacturing Platform
Read article "$12 million grant to develop breakthrough vaccine manufacturing platform"